- Clinical Interests
- Bone disorders related to neuroendocrine dysfunction
- Pituitary disease
- Pituitary tumors
- Reproductive Dysfunction
- Medical Education
- MD, New York University School of Medicine
- Residency, New York University School of Medicine
- Fellowship, Massachusetts General Hospital
- Board Certifications
- Diabetes & Metabolism
- Boston: Massachusetts General Hospital
- Insurances Accepted
- Aetna Health Inc.
- Beech Street
- Blue Cross Blue Shield - Blue Care 65
- Blue Cross Blue Shield - Indemnity
- Blue Cross Blue Shield - Managed Care
- Blue Cross Blue Shield - Partners Plus
- Cigna (PAL #'s)
- Fallon Community HealthCare
- Great-West Healthcare (formally One Health Plan)
- Harvard Pilgrim Health Plan - ACD
- Harvard Pilgrim Health Plan - PBO
- Health Care Value Management (HCVM)
- Humana/Choice Care PPO
- Medicare - ACD
- Neighborhood Health Plan - ACD
- Neighborhood Health Plan - PBO
- OSW - Maine
- OSW - New Hampshire
- OSW - Rhode Island
- OSW - Vermont
- Private Health Care Systems (PHCS)
- Senior Whole Health
- Tufts Health Plan
- United Healthcare (non-HMO) - ACD
- United Healthcare (non-HMO) - PBO
Note: This provider may accept more insurance plans than shown; please call the practice to find out if your plan is accepted.
- Patient Age Group
Dr. Lisa Nachtigall is the Co- Director of the Neuroendocrine Clinical Center at Massachusetts General Hospital and an Associate Professor of Medicine at Harvard Medical School. Her primary clinical focus is pituitary disorders and the treatment of patients with acromegaly. She has extensive clinical experience in neuroendocrine disorders and has published clinical research papers in this area. She has received awards for teaching and clinical investigation.
- Research Summary
- My study of how 100 patients with acromegaly came to diagnosis targeted education on this rare disease to professionals who most likely encounter it. I investigated a long acting somatostatin analog with a novel delivery system. I have contributed to several reviews on acromegaly and hyperprolactinemia and edited chapters on these topics. I have created an acromegaly database, including longitudinal data in over 350 patients, which will improve clinical practice strategies and serve as a resource for clinical investigation and as a model for database construction. I received an investigator initiated award to study long term treatment of acromegaly with somatostatin analogs.
Growth hormone deficiency after treatment of acromegaly: a randomized, placebo-controlled study of growth hormone replacement.
Miller KK, Wexler T, Fazeli P, Gunnell L, Graham GJ, Beauregard C, Hemphill L, Nachtigall L, Loeffler J, Swearingen B, Biller BM, Klibanski A. J Clin Endocrinol Metab. 2010 Feb;95(2):567-77. Epub 2010 Jan 8.
Effectiveness of self- or partner-administration of an extended-release aqueous-gel formulation of lanreotide in lanreotide-na?ve patients with acromegaly.
Salvatori R, Nachtigall LB, Cook DM, Bonert V, Molitch ME, Blethen S, Chang S; SALSA Study Group. Pituitary. 2010 Jun;13(2):115-22.
Zero Emerson Place
Boston MA, 02114-2217